Equities analysts expect that Solid Biosciences Inc (NASDAQ:SLDB) will post earnings of ($0.62) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Solid Biosciences’ earnings, with estimates ranging from ($0.66) to ($0.58). Solid Biosciences reported earnings of ($0.55) per share in the same quarter last year, which would suggest a negative year over year growth rate of 12.7%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 12th.

On average, analysts expect that Solid Biosciences will report full year earnings of ($2.85) per share for the current year, with EPS estimates ranging from ($3.05) to ($2.68). For the next fiscal year, analysts forecast that the company will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.17) to ($1.91). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Solid Biosciences.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.76) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.05.

A number of equities analysts have commented on the stock. ValuEngine upgraded shares of Solid Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Citigroup downgraded shares of Solid Biosciences from a “neutral” rating to a “sell” rating and set a $6.00 price objective on the stock. in a research report on Thursday, August 29th. Credit Suisse Group lowered shares of Solid Biosciences from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $7.00 to $6.00 in a research note on Tuesday, May 14th. Leerink Swann raised shares of Solid Biosciences from a “market perform” rating to an “outperform” rating in a research report on Monday, August 19th. Finally, Goldman Sachs Group lowered shares of Solid Biosciences from a “neutral” rating to a “sell” rating and cut their price target for the stock from $5.00 to $4.00 in a report on Tuesday, May 14th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Solid Biosciences currently has a consensus rating of “Hold” and a consensus target price of $8.67.

In related news, Director Life Sciences Maste Perceptive bought 2,822,581 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was acquired at an average price of $4.65 per share, with a total value of $13,125,001.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 31.20% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in SLDB. Quantamental Technologies LLC purchased a new stake in Solid Biosciences in the 2nd quarter worth approximately $42,000. Cubist Systematic Strategies LLC purchased a new position in Solid Biosciences during the 2nd quarter worth $70,000. Capital Fund Management S.A. acquired a new stake in Solid Biosciences during the 2nd quarter worth about $107,000. Parametric Portfolio Associates LLC acquired a new position in shares of Solid Biosciences during the 2nd quarter worth approximately $109,000. Finally, Trexquant Investment LP raised its position in shares of Solid Biosciences by 70.4% during the 2nd quarter. Trexquant Investment LP now owns 24,074 shares of the company’s stock worth $138,000 after acquiring an additional 9,947 shares in the last quarter. 46.29% of the stock is owned by institutional investors.

SLDB stock traded up $0.08 during trading on Friday, reaching $10.60. 570,148 shares of the company traded hands, compared to its average volume of 695,131. The business has a 50 day simple moving average of $7.38 and a 200 day simple moving average of $7.60. Solid Biosciences has a 12 month low of $4.32 and a 12 month high of $54.54. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.73 and a current ratio of 5.73. The company has a market capitalization of $454.01 million, a price-to-earnings ratio of -4.71 and a beta of 1.82.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Featured Article: CBOE Russell 2000® Volatility Index

Get a free copy of the Zacks research report on Solid Biosciences (SLDB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.